JWH-198 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor

agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...

. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a

binding affinity In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. The etymology stems from ''ligare'', which means 'to bind'. In protein-ligand binding, the ligand is usually a mol ...

at the CB₁ receptor of 10 nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring. It has been used mainly in molecular modelling of the cannabinoid receptors. In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-198 are Schedule I Controlled Substances.

References

JWH cannabinoids Aminoalkylindoles Naphthoylindoles 4-Morpholinyl compunds Designer drugs CB1 receptor agonists {{cannabinoid-stub

See also

References